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 Acinetobacter baumannii is an important opportunistic pathogen that mainly infects 
critically patients in intensive care units (ICU). The production of plasmid-mediated extended-
spectrum b-lactamases (ESBLs) is one of the most important mechanisms of resistance against 
b-lactam antibiotics. This study aimed to evaluate the prevalence of ESBLs in A. baumannii 
isolated from ICU of Ghaem hospital, Mashhad, Iran. A total of 140 A. baumannii isolates 
recovered from hospitalized patients in ICU of Ghaem hospital in Mashhad city from December 
2014 to March 2015. Identification of A. baumannii isolates carried out using biochemical 
laboratory methods and then confirmed by OXA-51 PCR screening.  Susceptibility testing 
performed using disk diffusion (Kirby-Bauer) method as recommended by CLSI guidelines. 
A. baumannii isolates screened for production of ESBLs using combination disk test. blaPER, 
blaGES, blaTEM, blaSHV, blaCTX, blaVEB and blaOXA-10 beta-lactamase genes detected 
using conventional PCR. The most antibacterial resistance was against cefuroxime ( 99.3%) 
and colistin was the most effective antibiotic. None of the isolates were ESBL producer by 
combination disk test. However, results of PCR revealed that the prevalence of blaPER, blaGES 
and blaTEM genes were 7.1%, 4.3% and 27.1%, respectively. blaCTX, blaVEB, and blaOXA-10 
were not found in any of isolates. According to the results, the high resistance was seen against 
selected antibiotics and the phenotypic tests are not sufficient alone for determination of ESBLs 
producer of A. baumannii isolates. So, molecular tests are also necessary for detection of these 
enzymes. 
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 B a c t e r i a  w h i c h  c o n s t i t u t e  t h e 
Acinetobacter genus were originally identified in 
the first decade of the 20th century. Acinetobacter is 
a genus of gram-negative bacteria belonging to the 
gammaproteobacterial1. Acinetobacter are rode-
shape during rapid growth and coco-bacillary in the 
stationary phase. They are generally encapsulated, 
nonmotile, aerobic, gram-negative organisms with 
tendency to retain crystal violet and therefore to 
be incorrectly identified as gram-positive cocci2. 
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Frequent misidentification of Acinetobacter 
as Neisseria or Moraxella on gram staining is 
readily clarified by the negative oxidase reaction 
of Acinetobacter. Additionally, Acinetobacter are 
catalase-positive. Hemolysis of red blood cells, 
acidification of glucose, growth at 44°C, and 
variability in carbon source uptake are few of the 
phenotypic characteristics applied to distinguish 
Acinetobacter strains3, A. baumannii isolates 
are more likely caused disease in patients with 
immunosuppression, serious underlying disease 
and people who are exposed to invasive procedures 
accompanying treatment with broad-spectrum 
antibiotics. Therefore, the spread of these species 
in ICU and burn wards is more. A. baumannii is 
an important cause of nosocomial infection, such 
as ventilator associated pneumonia(VAP), urinary 
tract infections, wound infections, and septicemia4. 
A. baumannii is a significant opportunistic 
pathogen that mainly infects critically ill patients 
in ICU5. 
 As known the ability of A. baumannii to 
achieve different mechanisms of resistance, also, 
resistance to all available common antibiotics as 
well as lack of new effective antimicrobial drugs 
are the most important causes of risk about this 
organism. A. baumannii isolates which are resistant 
to three or more classes of antibiotics are called 
multi-drug resistant strains (MDR). Increasing 
antibiotic resistance in Acinetobacter inhibits from 
appropriate management in antibiotic therapy6.
 A. baumannii has several innate resistance 
mechanisms to a number of antibiotics, such as 
aminopenicillins, first-and second- generation 
cephalosporins and chloramphenicol. Besides 
this, it has a considerable capacity to acquire 
mechanisms conferring resistance to broad-
spectrum b-lactams, carbapenems, aminoglycosides 
and fluoroquinolones. Beta lactam antibiotics 
(mainly carbapenems) are now the first drug of 
choice to treat this microorganism; however, 
in the last decade, resistance to carbapenems 
has appeared in hospitals worldwide owing to 
the production of beta-lactamase, change in 
permeability, increase in efflux, and modification 
of the affinity of penicillin-binding proteins (PBP
S
) 
in these bacteria7. Production of plasmid-mediated 
extended-spectrum b-lactamases (ESBLs) is one 
of the most important mechanisms of resistance 
against beta-lactam antibiotics. Many of these 
enzymes have evolved from TEM and SHV 
-lactamases, but recently a large number of ESBLs 
are related to TEM and SHV, such as GES and 
VEB, have been described8. Plasmid is accounted 
for distribution of the most beta lactamases; 
however, the gene encoding these enzymes may 
also be on the chromosome or transposable 
elements and integrons.
 ESBLs are also able to hydrolyze 
three and four generation cephalosporins and 
monobactams. ESBLs producer isolates are 
inhibited by b-lactamase inhibitors (clavulanic 
acid, sulbactam and tazobactam), At present, 
there are more than 300 different ESBL variants, 
and these have been clustered into nine different 
structures and these evolutionary families based 
on amino acid sequence9. TEM, CTX, SHV, GES, 
VEB, OXA-10 and PER are the major types. 
 In according to the information on the 
prevalence of these enzymes and antibacterial 
resistance pattern, control, prevention and treatment 
of this bacterium is important, thus, this study 
aimed to evaluate the prevalence of ESBLs in A. 
baumannii isolated from ICU of Ghaem hospital, 
Mashhad, Iran. 
 
MATERIALS AND METHODS
Bacterial sources
 A total of 140 A. baumannii isolates were 
recovered from hospitalized patients in ICU of 
Ghaem hospital in Mashhad city from December 
2014 to March 2015. All nonlactose fermenting 
members were subjected to microbiologic and 
biochemical tests such as; gram staining, oxidase, 
catalase, O/F, and growth at 42 °C on nutrient 
agar medium. For confirmation of A. baumannii 
isolates, API20NE kit (version 6.0, bio-Merieux, 
Marcy L’Etoile, France) was applied. Then until 
use, clinical isolates were stored in nutrient broth 
containing 20% glycerol at -80 °C.
Antibiotic Susceptibility Testing
 Antibiotic Susceptibil i ty Testing 
performed using modified Kirby-Bauer disk 
diffusion method based on CLSI guidelines6, 10. 
The potency of antibiotics disks was checked by 
reference strains Pseudomonas aeruginosa ATCC 
27853. After incubation for a period of 24 h, results 
were reported as sensitive, intermediate, or resistant 
according to the zone diameters. The antibiotics 
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used were imipenem (10 µg), meropenem (10 µg), 
colistin (25 µg), amikacin (30 µg), ceftazidime 
(30 µg), cefotaxime (30 µg), cefuroxime (30 µg), 
ceftriaxone (30 µg), cefepime (30 µg), ertapenem 
(10 µg) and ampicillin/sulbactam (10 µg).
Phenotypic Detection of Beta-Lactamase
 In phenotypic confirmation of ESBLs 
producers on Muller Hinton agar, the combination 
disc test (CDT) was applied as previously defined11. 
Cefotaxime (30 µ) or ceftazidime disks (30 µ) 
with or without clavulanate (10 µ) were used. 
After incubation of plates for 24 h at 37 °C, if 
the diameter of inhibition zone for each of these 
antibiotics in combination with clavulanic acid 
compared to antibiotics alone, increased by more 
than 5 mm, they defined as the ESBL-producing 
isolates, if no, isolates were reported as ESBL 
negative. P. aeruginosa ATCC 27853 was applied 
for quality control of isolates. 
DNA extraction and PCR 
 For DNA extraction and template 
preparation, the boiling method was used as 
previously described12and lastly samples stored 
at -20 °C, till use. The primer pair sequences 
designed by primer premier software for detection 
of ESBL genes in clinical isolates of A. baumannii 
using PCR technique are shown in Table 1. Of 
note, PCR of bla
OXA-51
-like gene was also used for 
confirmation of isolates identification. The PCR 
program for blaGES, blaCTX and blaPER genes was 
composed of an initial denaturation step (94 °C, 
5 min) followed by 30 cycles of denaturation step 
(94 °C, 1 min), annealing step (60 °C, 1 min), and 
extension step (72 °C, 1 min) with final extension 
(72 °C, 7 min). The DNA amplification program 
for blaoxa-10, blaSHV, blaVEB and blaTEM genes was 
similar to previous genes except that the annealing 
temperature was 51 °C. Components of PCR master 
mix (Amplicon, Denmark) were as follows; 1.5 
mM Mgcl
2
, 10 pmol/µl of each primer, 0.2 mM 
dNTPs, 1U Taq DNA polymerase, 1X PCR buffer 
and 50 ng/µl DNA. PCR products were analyzed 
using 2% agarose gel electrophoresis (Cinaagen, 
IRAN). And 50bp DNA ladder (Fermentas 
company product) was used to detect the specific 
PCR products related to the bla genes. Then, results 
were observed under UV light gel documentation 
system.
Sequencing of PCR products
 The PCR products of three samples for 
each mentioned gene were subjected to direct 
sequencing and the nucleotide sequences were 
evaluated and analyzed with CLUSTAL W2 and 
BLAST softwares.
Data analysis
 SPSS software (version 22, Chicago, 
IL, USA) was used for performing the statistical 
analy sis using chi-squire and Fisher’s exact tests. 
Also, P-value<0.05 was con sidered as significant 
statistically.
RESULTS
 In this study, a total of 140 isolates A. 
baumannii collected from ICU of Ghaem hospital 
in Mashhad, Iran, from December 2014 to March 
Table 1. Primer sequences of ESBL genes amplified by PCR
Primer Name 5'- primer sequence - 3'  Size, bp
  
F- GES CGCTTCATTCACGCACTATTACTG 682
R- GES TCTCTCCAACAACCCAATCTTTAGG 
F- VEB GCCAGAATAGGAGTAGCAAT 547
R- VEB GGTTACTTCCTGTTGTTGTT 
F-TEM CAGTGCTGCCATAACCAT 271
R-TEM CGCCTCCATCCAGTCTAT 
F- SHV TATTCGCCTGTGTATTATCTCC 378
R-SHV CTGTTATCGCTCATGGTAATG 
F-OXA GCGGCACCTGAATATCTA 165
R-OXA TCTTAGCGGCAACTTACTT 
F-PER GCAATACTCGGTCTCGCACAG 461
R-PER TTCGGCTTGACTCGGCTGAG 
F-CTX GCGACAATACTGCCATGAATAAGC 349
R-CTX ATATCGTTGGTGGTGCCATAATCTC 
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Table 2. Antimicrobial susceptibility pattern of A. baumannii isolates
Antimicrobials Resistance,  Intermediate,  Sensitivity,
 No. (%) No. (%) No. (%)
imipenem 137 (97.9) 0 3 (2.1)
meropenem 138 (98.6) 0 2 (1.4)
colistin 3 (2.1) 0 137 (97.9)
amikacin 94 (67.1) 8 (5.7) 38 (27.1)
ceftazidime 135 (96.4) 0 5 (3.6)
cefotaxime 137 (97.9) 1 (0.7) 2 (1.4)
cefuroxime 139 (99.3) 0 1 (0.7)
ceftriaxone 137 (97.9) 1 (0.7) 2 (1.4)
cefepime 137 (97.9) 0 3 (2.1)
ertapenem 138 (98.6) 0 2 (1.4)
ampicillin/sulbactam 136 (97.1) 2 (1.4) 2 (1.4)
Table 3. Frequency distribution of ESBLs genes in 
clinical A. baumannii isolates 
Genes  Number Genes  Number (%)
blaTEM 38(27.1%) blaCTX 000
blaSHV 9(6.4%) blaOXA-10 
blaPER 10(7.1%) blaVEB 
blaGES 6(4.2%)  
Table 4. Frequency distribution of ESBLs genes in A. baumannii 
isolates based on types of clinical samples
Genes  Trashes,  Urine,  Wound,  Blood   P- value 
 N=71   N=50  N=10   culture, N=9
blaTEM 18(25.4%) 15(30%) 2(20%) 3(33.3%) 0.86
blaSHV 5(7%) 3(6%) 0 1(11.1%) 0.78
blaPER 3(4.2%) 6(12%) 1(10%) 0 0.32
blaGES 2(2.8%) 4(8%) 0 0 0.40
blaCTX 0 0 0 0 0.00
blaOXA-10 0 0 0 0 0.00
blaVEB 0 0 0 0 0.00
2015. The sources of isolates were as follows; 
Trashes 71 (50.7%), Urine 50 (35.7%), Wound 
10 (7.2%) and Blood Culture 9 (6.4%). Overall, 
51.4%, 48.6% of the hospitalized patients were 
female and male, respectively. The most frequent 
isolates of A. baumannii (with prevalence of 40%) 
were in the age group 31-50 years. Also, the most 
rates of isolates (with prevalence of 51.4%) were 
seen in female than male. 
 As shown in Table 2,  results  of 
antibacterial susceptibility pattern revealed that 
in A. baumannii the high resistance was to all 
antibiotics except colistin, as resistance rates to 
imipenem, meropenem, ceftazidime, cefotaxime, 
cefuroxime, ceftriaxone, Cefepime, ertapenem and 
ampicillin/sulbactam were 97.9%, 98.1%, 96.4%, 
97.9%, 99.3%, 97.9%, 97.9%,98.6% and 97.1%, 
respectively. The most effective antibiotic against 
A. baumannii was colistin with susceptibility 
97.9% followed by amikacin with sensitivity 27.1 
% (Table 2).  
 It was also presented that none of the 
isolates were ESBL producers by Combination disk 
method. Although A. baumannii isolates exhibited 
a high degree of resistance to third-generation 
cephalosporins but they did not produce ESBL.
 PCR revealed that the prevalence of 
blaPER, blaGES, blaTEM genes were 7.1%, 4.3% 
and 27.1%, respectively. blaCTX, blaVEB, and 
blaOXA-10 were not found in any of isolates (Table 
3 and Figures 1-3). 
 A. baumannii isolates which at one time 
had two ESBL genes were: blaPER/blaGES 2(1.4%), 
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Fig. 1. Agarose gel electrophoresis for analyzing of 
blaoxA-51 gene amplification. Lane 1: 50bp DNA Ladder, 
lanes 2-8:  Isolates containing the fragment of 353bp 
blaoxA-51 gene, lane 9: negative control
Fig. 2. Agarose gel electrophoresis for blaPER and blaGES 
genes amplification. Lane 1: 50bp DNA ladder, lane 2: 
isolate harboring blaPER (461 bp) and lane 3: isolate with 
682 bp blaGES gene. 4: negative control
Fig. 3. Agarose gel electrophoresis for amplification 
analysis of blaTEM and blaSHV genes. Lane 1: 50bp DNA 
ladder, lanes 2: isolate without blaTEM and blaSHV genes, 
lanes 3-4:   isolates with blaTEM (271 bp), lane 5: negative 
control for reaction with blaTEM primer, lane 6: isolate 
with 378 bp blaSHV gene, lane 7: negative control for 
reaction with blaSHV primer
blaSHV/blaGES 2(1.4%), blaSHV/blaTEM 2(1.4%), 
blaGES/blaTEM 1(0.7%).     
 In addition, results showed that there 
no correlation was found between prevalence 
of ESBLs genes and types of clinical samples 
(p>0.05), as per Table 4. 
DISCUSSION 
 A. baumannii is mostly found in hospital 
settings and is nowadays noticed more than ever 
due to its survival ability in such environments and 
causing nosocomial infections. In this study, among 
the aminoglycosides, amikacin was resistant in 
67.1% of cases and in other groups; cephalosporins, 
carbapenems, and penicillin were almost 100% 
resistant, indicating multiple drug resistance in 
these isolates. Colistin was the most effective 
antibiotic (97.9%).  Our results demonstrated that 
the rate of resistance was significantly lower in 
colistin compared to other antibiotics. The possibly 
reason for low resistance to this antibiotic may 
be owing to its infrequent prescription during the 
recent period. In a study conducted by Shahcheraghi 
et al (2009) on A. baumannii isolated from patients 
hospitalized in Tehran hospitals showed a large 
proportion of isolates were resistant to ceftriaxone 
(96.8%), cefotaxime (95.7%), ceftazidime (78.9%), 
and cefexime (100%), while 95.8% of isolates were 
susceptible to colistin, which their findings were 
consistent with current study. This study, like the 
studies carried out by Tseng et al in China in 2007 
13 and Smolyakov et al in 200014, confirmed that 
most isolates were resistant to ceftazidime and 
cefepime. Regarding the present results and similar 
studies, due to over-administration of the third 
generation cephalosporins and lack of observing 
the hygienic principles in the community, a 
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considerable resistance has been developed against 
this generation of cephalosporins. So, based these 
findings, the third generation cephalosporins are 
not good choice for treatment of infections caused 
by MDR A. baumannii isolates.
 The study conducted by Srinivasan 
and colleagues in Ohio, USA15, more than 80% 
of the isolates were resistant to a wide range of 
cephalosporins and 20% to imipenem, while in 
our study, resistance to imipenem was more than 
90%, which this dissimilarity might be due to 
unnecessary overuse of antibiotics. An another 
study conducted by Akan et al in 2002, in Turkey 
on 277 A. baumannii isolates revealed that the 
resistance rate to imipenem and amikacin was 
53.6% and 59.8%, respectively16, in contrast, this 
rate was much higher in our study and also in 
comparable above mentioned ones. All of studies 
stated here used disk diffusion agar method to 
evaluate antibiotic susceptibility similar to our 
study. Therefore, the difference in results could 
be attributed to diversity in types of isolates, 
variety in antibiotic disks used, and difference 
in geographical regions of the studies and 
policies of infection control17. Thus, the regional 
determination of antibiotic susceptibility of A. 
baumannii can act as a suitable guide for effective 
use of routine antibiotics. Since in this study 
and similar ones, the most A. baumannii isolates 
(50.7%) were obtained from pulmonary secretions, 
it appears that the respiratory tract is the most 
involved in infections caused by A. baumannii. 
So, disinfection and sterilization of equipment and 
respiratory devices like respiratory is one of the 
ways for prevention of infection dissemination. 
Based on the studies conducted in our country 
(Iran) and through study reported by Sharif et al 
in 2013, 51% of A. baumannii isolates had the 
wide-range beta-lactamase-producing phenotype18. 
Also, Owlia et al in 2012, in Tehran reported that 
21% of A. baumannii isolates had the wide-range 
beta-lactamase-producing phenotype19. Similarly, 
this rate was reported 28% in a study conducted 
by Sinha et al in India in 20078.  Shakibaie et al 
in 2012 identified only 3 ESBL-producing among 
100 A. baumannii isolates20.  The study by Jazani 
et al (2010) reported only 1 ESBL-producing 
isolate from among 48 A. baumannii isolates 
recovered from clinical samples of patients 
hospitalized in burn hospital, Tehran21. In present 
study, we used the combination disk method similar 
to the method used in the mentioned studies, there 
was no positive test regarding phenotype. One 
probable reason for lack of production of extended 
b-lactamase-producing phenotype in the present 
study, compared to other studies, may be increased 
expression of AmpC genes and also beta-lactamases 
and metallo beta-lactamase enzymes. It is also 
possible that mechanisms other than extended 
b-lactamase like secretary pumps and variations in 
porins induce resistance in this organism. Indeed, 
resistance in A. baumannii is associated with a 
combination of various mechanisms including 
acquisition of b-lactamases, stable induction of 
AmpC, reduced permeability, changes in penicillin 
binding proteins, and somewhat, with an increase 
in Efflux pumps21. Performing of phenotypic tests 
alone is not able to determine the ESBL-producing 
isolates in A. baumannii. Some molecular tests 
need be performed to determine the presence of 
ESBL enzymes. 
 The blaOXA-51 gene is considered as a 
chromosol component of A. baumannii isolates 
which can used to identify this organism,22for this 
reason in present study we used blaOXA-51 gene for 
confirmation of the A. baumannii isolates.
 Azhari and et al in 2010 in Tabriz 
indicated that among 100 isolates of A. baumannii 
from different clinical samples, PER gene was 
not found in any of samples23. The first report 
of presence of PER gene was detected in a study 
conducted by Farajnia and et al in 2013 in Tabriz, 
wherein its prevalence was 51.7% 24 which was 
higher than over results. But another in 2007 in 
Argentina presented that among 1 out of 6 isolates 
was positive for PER gene25. 
 Shahcheraghi et al in 2009 in Tehran 
revealed that of 95 isolates, 12.8% were reported 
positive for TEM26 while this rate in study carried 
out by Sharif and et al in 2012 in Tehran was 56%18. 
In another one in America in 2010, occurrence of 
TEM was 37%27, which is partly in line with present 
study.   
 GES was first reported in the study by 
Shahcheraghi et al in 2011 in Tehran, Iran, in which 
2 out of 100 A. baumannii isolates were resistant 
to imipenem26. Furthermore, in the study carried 
out by Bogaerts et al in 2009 in Belgium, 9 out 
of 125 isolates were reported positive for GES 
gene which is relatively similar to our study with 
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6 positive isolates28. Also VEB was first reported 
in the study performed by Poirel et al in 2003 in 
France, in which 7 cases (58.3%) out of 12 A. 
baumannii isolates were positive for VEB gene29. 
In the study conducted by Pasteran and colleagues 
in 2006 in USA, 47.6% of isolates possessed the 
VEB gene[30]. Moreover, in the study carried out 
by Farajnia et al in 2009 in Tabriz, Iran, 10% out 
of 100 A. baumannii isolates were reported positive 
for VEB gene24, in contrast none of isolates were 
positive for VEB gene in our study. 
 Vafaei and et al presented of 130 A. 
baumannii isolates, 19% of those were positive for 
CTX gene31. But in the study conducted by Ramoul 
and colleagues in 2013, CTX was not found in any 
of the isolates32, which is close to our results.  
 Several studies suggested varying 
distribution of resistant genes in different 
geographical regions. Geographical distance and 
also pattern of antibiotic usage can predispose 
to emergence of resistant genes in different 
geographical areas. As Beta-lactamase-producing 
isolates constitute a lower percentage compared 
to Beta-lactam-resistant isolates, it seems that in 
addition to the production of Beta-lactamases, 
other factors like the presence of Efflux pumps and 
cellular wall canals or purines also contribute to the 
creation of resistance. Due to the capacity of these 
isolates for transmitting resistance genes to other 
clinical isolates, the exact identification of Beta-
lactamases genes contributing resistance is of most 
importance for care, treatment, and epidemiologic 
studies on transmission methods in hospitals33. 
 The high resistance of isolates to third 
and fourth generation of cephalosporins compared 
to the low number of ESBL producing isolates, 
proposed another resistance mechanisms such 
as secretory pump, purines, biofilm information 
involved in development of resistance.
 Hence, the development in policies of 
antibiotic prescription and infection control are 
more critical to pre vent the spreading of such 
resistant infectious organisms. 
CONCLUSION
 According to the results, the high 
resistance was seen against selected antibiotics 
and the phenotypic tests are not sufficient alone for 
determination of ESBLs producer of A. baumannii 
isolates. So, molecular tests are also necessary for 
detection of these enzymes.
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